ZBTB20-AS2

Across TCGA pan-cancer cohorts, ZBTB20-AS2 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated ZBTB20-AS2 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZBTB20-AS2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZBTB20-AS2 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

BLCA, STAD, and LIHC are the cancer types where ZBTB20-AS2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	II,III,IV	0.099	0.619	<.001	171	view →
STAD	OS	Median	All	0.762	0.645	.008	51	view →
LIHC	OS	Tertile	All	0.031	0.775	<.001	45	view →
READ	DFS	Tertile	III,IV	0.255	0.757	.008	45	view →
KIRP	DFS	Tertile	II,III,IV	0.122	0.626	.032	18	view →
ESCA	OS	Quartile	II,III,IV	0.300	0.512	.017	11	view →
GBM	OS	Tertile	All	0.196	0.420	.040	9	view →
LUSC	DFS	Tertile	II,III,IV	0.218	0.594	.044	9	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ZBTB20-AS2–BLCA (DFS)

Open the BLCA breakdown →